Effect of CYP3A inhibition on vesnarinone metabolism in humans

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 5, 1998, Pages 506-511

  Wandel, Christoph ^b   Lang, Chim C ^b   Cowart, Doug C ^b   Girard, Armand F ^b   Bramer, Steve ^b   Flockhart, David A ^b   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE; ERYTHROMYCIN; OPC 18692; PIPERANOMETOZINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; MALE; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; QUINOLINES;

EID: 0031862835     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90101-1     Document Type: Article

References (19)

1. Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA, Schwartz A. Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212. Naunyn Schmiedebergs Arch Pharmacol 1988; 338:692-8.
2. Lathrop DA, Varro A, Schwartz A. Rate-dependent electrophysiological effects of OPC-8212: comparison to sotalol. Eur J Pharmacol 1989;164:487-96.
3. Feldman AM, Pepine CJ, Bristow MR, Hendrix GH, Powers ER, Bertolet B, et al. Incidence of vesnarinone induced neutropenia: The U.S. experience [abstract]. Circulation 1993;88(suppl):I301.
4. Feldman A, Young J, Bourge R, Carson P, Jaski B, DeMets D, et al. Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VesT) [abstract]. J Am Coll Cardiol 1997;29(2 suppl A):64A.
5. Miyamoto G, Sasabe H, Tominaga N, Uegaki N, Tominaga M, Shimizu T. Metabolism of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212) in the rat, mouse, dog, monkey and human. Xenobiotica 1988;18:1143-55.
6. Guengerich FP, Böcker RH. Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines. J Biol Chem 1988;263:8168-75.
7. Skiles GL, Yost GS. Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole. Chem Res Toxicol 1996;9:291-7.
8. Warren JT, Gilbert LI. Metabolism in vitro of cholesterol and 25-hydroxycholesterol by the larval prothoracic glands of Manuca sexta. Int J Biochem Mol Biol 1996; 26:917-29.
9. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among 3 putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
10. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-14.
11. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Writhon SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450: studies in rats and patients. J Clin Invest 1989;83:688-97.
12. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
13. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
14. McKinnon RA, Burgess WM, de la M'Hall P, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36:259-67.
15. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A mediated metabolism. Clin Pharmacol ther 1996;59:491-502.
16. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60: 14-24.
17. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
18. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. the effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
19. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.